Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Strait of Hormuz Shipping Crisis Deepens as Traffic Plunges Amid Iran-U.S. Tensions 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
GAITHERSBURG, Md., Feb. 22, 2016 -- Novavax, Inc. (Nasdaq:NVAX), a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its fourth quarter and full year 2015 financial and operating results prior to the open of U.S. financial markets on Monday, February 29, 2016.
Management will host a conference call to discuss the quarterly and year-end financial results and provide an update on corporate activities.
Conference call details are as follows:
| Date: | February 29, 2016 | |
| Time: | 8:00 am U.S. Eastern Time (ET) | |
| Dial-in number: | (877) 212-6076 (Domestic) or (707) 287-9331 (International) | |
| Via web: | www.novavax.com, “Investors”/ “Events” | |
Conference call replay:
| Dates: | Starting at 11:00 am ET, February 29, 2016 until midnight March 7, 2016 | |
| Dial-in number: | (855) 859-2056 (Domestic) or (404) 537-3406 (International) | |
| Passcode: | 45346424 | |
| Via web: | www.novavax.com, “Investors”/ “Events” | |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M™ adjuvant technology are the foundation for groundbreaking innovation that improves global health through safe and effective vaccines.
Contact: Novavax, Inc. Barclay A. Phillips SVP, Chief Financial Officer and Treasurer Andrea N. Flynn, Ph.D. Senior Manager, Investor Relations [email protected] 240-268-2000
